News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26 Results
Type
Article (1)
Press Release (25)
Section
Business (6)
Deals (3)
Drug Development (13)
News (18)
Tag
Alliances (1)
Clinical research (12)
Earnings (1)
Events (1)
IPO (2)
Mergers & acquisitions (1)
People (4)
Phase I (3)
Phase II (9)
Preclinical (1)
Date
Last 365 days (1)
2024 (1)
2022 (2)
2021 (5)
2019 (3)
2018 (4)
2017 (3)
2015 (2)
2014 (1)
2013 (3)
2012 (2)
Location
Asia (1)
Europe (1)
26 Results for "adynxx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Adynxx Reports Third Quarter 2019 Financial Results
Adynxx, Inc. announced financial results and provided a business update for the quarter ended September 30, 2019.
November 14, 2019
·
8 min read
Business
Adynxx and twoXAR Form Collaboration to Discover and Develop Treatments for Endometriosis
Drug Development Approach Combines twoXAR’s Artificial Intelligence-Driven Discovery Technology with the Adynxx Team’s Development Experience
November 15, 2018
·
4 min read
Deals
Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation
Alliqua BioMedical, Inc. and Adynxx, Inc. today announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis.
October 12, 2018
·
12 min read
Biotech Bay
Adynxx Announces Notice Of Award For $5.7M In Federal Grant Funding
Award intended to fund Phase 2 study of brivoligide in patients undergoing mastectomy
December 13, 2018
·
6 min read
Drug Development
Adynxx Announces Results of the ADYX-004 Phase 2 Study of Brivoligide (AYX1) for the Treatment of Post-Surgical Pain
Brivoligide reduced post-surgical pain, opioid use and time to achieve mild pain in an underserved patient population that suffers from inadequate pain relief following surgery
April 12, 2018
·
6 min read
Biotech Bay
Adynxx Release: Biotech Announces Closing Of Series B Financing
January 10, 2017
·
3 min read
Business
Terns Pharmaceuticals Announces Leadership Changes
Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development.
May 8, 2024
·
6 min read
Drug Development
Adynxx Completes Enrollment In ADYX-004, A Phase II Study Of Brivoligide (AYX1), Lead Compound For The Treatment Of Post-Surgical Pain
October 4, 2017
·
3 min read
Drug Development
Adynxx Initiates ADYX-004, A Phase II Study Of AYX1, Lead Compound For The Treatment Of Post-Surgical Pain
March 1, 2017
·
4 min read
Drug Development
Adynxx Reports Positive Results For Phase 2b Study Of AYX1
August 11, 2015
·
4 min read
1 of 3
Next
